VIRHealthcare · BiotechnologyThe 10 Wall Street analysts covering Vir Biotechnology, Inc. hold a median 12-month price target of $21 — +85.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 31 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Vir Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Accruals (48): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (36): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on VIR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +85.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $20 → $22 |
| 11 June 2026 | Morgan Stanley | Maintains | Overweight | — |
| 11 June 2026 | Morgan Stanley | Maintains | Overweight | $23 → $27 |
| 3 June 2026 | Leerink Partners | Maintains | Outperform | — |
| 4 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 Feb 2026 | Barclays | Maintains | Overweight | — |
| 24 Feb 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 24 Feb 2026 | Morgan Stanley | Maintains | Overweight | — |
| 24 Feb 2026 | Needham | Maintains | Buy | — |
| 9 Feb 2026 | Needham | Reiterates | Buy | — |
| 30 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Sept 2025 | Evercore ISI Group | Initiates | Outperform | — |
| 27 Aug 2025 | B of A Securities | Upgrade | Buy | — |
| 11 July 2025 | Raymond James | Initiates | Outperform | — |
| 22 May 2025 | Needham | Reiterates | Buy | — |
| 12 May 2025 | Needham | Maintains | Buy | — |
| 17 Apr 2025 | Goldman Sachs | Maintains | Buy | — |
| 28 Feb 2025 | Barclays | Maintains | Overweight | — |
| 28 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VIR appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Vir Biotechnology, Inc. returned +90.6% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 19% of US stocks
Cheaper than 44% of US stocks
Cheaper than 81% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 87% of US stocks
Higher than 7% of US stocks
Higher than 29% of US stocks
Higher than 23% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vir Biotechnology, Inc. has a market value of $1.9B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $302.6M. The latest quarter grew 19582.5% year on year.
Net income over the same four quarters: −$251.7M, a −83.2% net margin.
Diluted earnings per share, trailing twelve months: $−1.86.
Free cash flow in the twelve months to 30 June 2026: −$203.6M.
Trailing P/E: −3.6×; forward P/E: −4.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Vir Biotechnology, Inc. employs 367 people — $824K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Vir Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Vir Biotechnology announced that Suzanne Topalian, M.D., will join its Board of Directors effective October 27, 2026. Topalian is a cancer immunotherapy professor and leader at Johns Hopkins University and its Kimmel Cancer Center.
Why it matters — VIR watchers may note the addition of an experienced cancer immunotherapy academic and program leader to the board.
The article highlights pharma collaborations around VIR’s PRO-XTEN platform and near-term potential catalysts, including ECLIPSE hepatitis delta readouts and VIR-5818 oncology data. It also notes prior hepatitis delta results and competition from GILD and MIRM.
Why it matters — VIR watchers may focus on the upcoming clinical readouts and whether the platform collaborations and prior data translate into further evidence of differentiation.
Vir Biotechnology announced a conference call for 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, November 4, to provide a corporate update and discuss third-quarter 2026 financial results.
Why it matters — The call gives VIR watchers an opportunity to hear the company’s update and review results for the quarter ended September 30, 2026.
Vir Biotechnology announced a collaboration with Gilead Sciences to develop three novel T-cell engagers (TCEs) targeting solid tumors.
Why it matters — The deal adds a solid-tumor treatment development collaboration to Vir’s activities.
Vir Biotechnology announced a collaboration and license agreement with Gilead to discover and engineer three PRO-XTEN dual-masked T-cell engager development candidates for selected solid tumor-associated antigens. Gilead will hold an exclusive license to develop and commercialize the candidates.
Why it matters — The agreement involves Vir’s T-cell engager discovery and protein-engineering capabilities and grants Gilead exclusive development and commercialization rights to the resulting candidates.
The 10 Wall Street analysts covering Vir Biotechnology, Inc. have a median 12-month price target of $21, with estimates ranging from $15 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Vir Biotechnology, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vir Biotechnology, Inc. 93 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Vir Biotechnology, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +85.8% from the last close, and Ticker Nerd's factor model ranks Vir Biotechnology, Inc. 93 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Vir Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VIR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $30 over the next 12 months.
Vir Biotechnology, Inc. returned +90.6% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer.
The most recent item we track (Business Wire, 28 Oct 2026): "Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors". Vir Biotechnology announced that Suzanne Topalian, M.D., will join its Board of Directors effective October 27, 2026. Topalian is a cancer immunotherapy professor and leader at Johns Hopkins University and its Kimmel Cancer Center.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. The company centers its work on immune-based approaches, including antibody therapeutics and T cell-engaging technologies, to address conditions with significant unmet medical need. Its current portfolio includes programs for chronic hepatitis delta and chronic hepatitis B, alongside multiple solid-tumor candidates built on its PRO-XTEN masking platform. Vir Biotechnology also maintains preclinical research across infectious diseases and oncology, reflecting a pipeline that spans both treatment and prevention. Headquartered in San Francisco, California, Vir Biotechnology plays a role in the broader biotechnology market as a research-driven developer of advanced therapeutic candidates.
CEO Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. · 367 employees · United States · https://www.vir.bio
